Latest news with #SanfordI.Weill
Mid East Info
13-05-2025
- Health
- Mid East Info
Tirzepatide Outperforms Semaglutide by 47% in Weight Loss - Middle East Business News and Information
Participants achieved an average weight loss of 20.2% with tirzepatide vs. 13.7% with semaglutide In key secondary endpoints, tirzepatide was superior to semaglutide across all weight reduction targets and waist circumference reduction Dubai, United Arab Emirates, May, 2025 – A clinical study has presented detailed findings from SURMOUNT-5, a phase 3b open-label clinical trial, evaluating the safety and efficacy of tirzepatide, a dual GIP and GLP-1 receptor agonist, compared to semaglutide, a mono GLP-1 receptor agonist, in adults living with obesity, or overweight with at least one weight-related medical problem and without diabetes. At 72 weeks, tirzepatide met the primary endpoint and all five key secondary endpoints, demonstrating superiority compared to semaglutide across the trial. The detailed results were presented at the 32nd European Congress on Obesity (ECO) and simultaneously published in The New England Journal of Medicine. For the primary endpoint, participants treated with tirzepatide achieved an average weight reduction of 20.2% compared to 13.7% with semaglutide at 72 weeks using treatment-regimen estimand,1 a 47% greater relative weight loss. Participants using tirzepatide lost an average of 50.3 lbs (22.8 kg) and participants on semaglutide lost an average of 33.1 lbs (15.0 kg).2 In key secondary endpoints, tirzepatide was superior across all weight reduction targets with 64.6% of participants treated with tirzepatide achieving at least 15.0% weight loss compared to 40.1% on semaglutide. Additionally, participants treated with tirzepatide achieved a superior average waist circumference reduction of 7.2 in (18.4 cm), while those treated with semaglutide saw an average reduction of 5.1 in (13.0 cm). 'Thanks to the latest advancements in obesity management medications, more physicians and patients are witnessing significant weight reduction beyond what they have seen before' said Louis J. Aronne, MD, FACP, DABOM, director of the Comprehensive Weight Control Center and the Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medicine, obesity expert at New York-Presbyterian/Weill Cornell Medical Center, and investigator of SURMOUNT-5. 'The SURMOUNT-5 head-to-head results demonstrated tirzepatide led to greater weight reduction compared to semaglutide, providing further evidence to support tirzepatide as an effective option for obesity management.' Primary and Key Secondary Endpoints: Tirzepatide Semaglutide Primary Endpoint Avg % weight loss -20.2% -13.7% Key Secondary Endpoints Achieved ≥10% weight loss 81.6% 60.5% Achieved ≥15% weight loss 64.6% 40.1% Achieved ≥20% weight loss 48.4% 27.3% Achieved ≥25% weight loss 31.6% 16.1% Waist circumference reduction -18.4 cm -13.0 cm 'In the SURMOUNT-5 trial, tirzepatide demonstrated a significantly higher magnitude of weight reduction compared to semaglutide across all comparisons,' said Leonard Glass, MD, FACE, senior vice president, global medical affairs, Lilly. 'These data confirm tirzepatide as a leading treatment option for people living with obesity and equip healthcare providers with critical insights to make well-informed treatment decisions as part of a comprehensive obesity care plan.' The safety profile of tirzepatide in SURMOUNT-5 was consistent with previous SURMOUNT trials. Adverse events reported during the trial were primarily gastrointestinal-related and were generally mild to moderate in severity. During the trial, 6.1% of participants taking tirzepatide discontinued treatment due to adverse events, compared to 8.0% of participants taking semaglutide. However, the study was not powered to compare the safety and tolerability of tirzepatide and the safety and tolerability of semaglutide. About SURMOUNT-5: SURMOUNT-5 (NCT05822830) was a 72-week, multi-center, randomized, open-label, phase 3b trial evaluating the efficacy and safety of tirzepatide compared with semaglutide in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea (OSA) or cardiovascular disease, who did not have diabetes. Participants in both treatment groups received counseling on a reduced-calorie diet and increased physical activity. The trial randomized 751 participants across the U.S. and Puerto Rico in a 1:1 ratio to receive maximum tolerated dose of tirzepatide (10 mg or 15 mg) or semaglutide (1.7 mg or 2.4 mg). With tirzepatide, 89.3% received at least one dose of the 15 mg dose and with semaglutide 92.8% received at least one dose of the 2.4 mg dose. The primary objective of the study was to demonstrate tirzepatide's superiority in percent change from baseline in body weight at 72 weeks compared to semaglutide's. About tirzepatide: Tirzepatide is a once-weekly dual GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist. Tirzepatide is a single molecule that activates the body's receptors for GIP and GLP-1, which are natural incretin hormones. Both GIP and GLP-1 receptors are found in areas of the human brain important for appetite regulation. Tirzepatide decreases calorie intake, and the effects are likely mediated by affecting appetite. Studies of tirzepatide in chronic kidney disease (CKD) and in morbidity/mortality in obesity (MMO) are ongoing. About Lilly: Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.
Web Release
12-05-2025
- Health
- Web Release
Tirzepatide Outperforms Semaglutide by 47% in Weight Loss
By Editor_wr On May 12, 2025 A clinical study has presented detailed findings from SURMOUNT-5, a phase 3b open-label clinical trial, evaluating the safety and efficacy of tirzepatide, a dual GIP and GLP-1 receptor agonist, compared to semaglutide, a mono GLP-1 receptor agonist, in adults living with obesity, or overweight with at least one weight-related medical problem and without diabetes. At 72 weeks, tirzepatide met the primary endpoint and all five key secondary endpoints, demonstrating superiority compared to semaglutide across the trial. The detailed results were presented at the 32nd European Congress on Obesity (ECO) and simultaneously published in The New England Journal of Medicine. For the primary endpoint, participants treated with tirzepatide achieved an average weight reduction of 20.2% compared to 13.7% with semaglutide at 72 weeks using treatment-regimen estimand,1 a 47% greater relative weight loss. Participants using tirzepatide lost an average of 50.3 lbs (22.8 kg) and participants on semaglutide lost an average of 33.1 lbs (15.0 kg).2 In key secondary endpoints, tirzepatide was superior across all weight reduction targets with 64.6% of participants treated with tirzepatide achieving at least 15.0% weight loss compared to 40.1% on semaglutide. Additionally, participants treated with tirzepatide achieved a superior average waist circumference reduction of 7.2 in (18.4 cm), while those treated with semaglutide saw an average reduction of 5.1 in (13.0 cm). 'Thanks to the latest advancements in obesity management medications, more physicians and patients are witnessing significant weight reduction beyond what they have seen before' said Louis J. Aronne, MD, FACP, DABOM, director of the Comprehensive Weight Control Center and the Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medicine, obesity expert at New York-Presbyterian/Weill Cornell Medical Center, and investigator of SURMOUNT-5. 'The SURMOUNT-5 head-to-head results demonstrated tirzepatide led to greater weight reduction compared to semaglutide, providing further evidence to support tirzepatide as an effective option for obesity management.' Primary and Key Secondary Endpoints: Tirzepatide Semaglutide Primary Endpoint Avg % weight loss -20.2% -13.7% Key Secondary Endpoints Achieved ?10% weight loss 81.6% 60.5% Achieved ?15% weight loss 64.6% 40.1% Achieved ?20% weight loss 48.4% 27.3% Achieved ?25% weight loss 31.6% 16.1% Waist circumference reduction -18.4 cm -13.0 cm 'In the SURMOUNT-5 trial, tirzepatide demonstrated a significantly higher magnitude of weight reduction compared to semaglutide across all comparisons,' said Leonard Glass, MD, FACE, senior vice president, global medical affairs, Lilly. 'These data confirm tirzepatide as a leading treatment option for people living with obesity and equip healthcare providers with critical insights to make well-informed treatment decisions as part of a comprehensive obesity care plan.' The safety profile of tirzepatide in SURMOUNT-5 was consistent with previous SURMOUNT trials. Adverse events reported during the trial were primarily gastrointestinal-related and were generally mild to moderate in severity. During the trial, 6.1% of participants taking tirzepatide discontinued treatment due to adverse events, compared to 8.0% of participants taking semaglutide. However, the study was not powered to compare the safety and tolerability of tirzepatide and the safety and tolerability of semaglutide. Tirzepatide Outperforms Semaglutide by 47% in Weight Loss Comments are closed.
India Gazette
12-05-2025
- Health
- India Gazette
Weight loss drug Mounjaro shown more effective than Wegovy, claims Pharma company
New Delhi [India], May 12 (ANI): Eli Lilly and Company announced on Monday detailed results from SURMOUNT-5, a phase 3b open-label clinical trial, evaluating the safety and efficacy of tirzepatide, a dual GIP and GLP-1 receptor agonist, compared to semaglutide, a mono GLP-1 receptor agonist, in adults living with obesity, or overweight with at least one weight-related medical problem and without diabetes, according to a press statement. According to Eli Lilly, participants reduced 20.2 per cent weight with tirzepatide in comparison to 13.7 per cent with semaglutide across the trials. At 72 weeks, tirzepatide met the primary endpoint and all five key secondary endpoints, demonstrating superiority compared to semaglutide across the trial. The detailed results were presented at the 32nd European Congress on Obesity (ECO) and simultaneously published in The New England Journal of Medicine. The statement added, 'For the primary endpoint, participants treated with tirzepatide achieved an average weight reduction of 20.2 per cent compared to 13.7 per cent with semaglutide at 72 weeks using treatment-regimen estimand,1 47 per cent greater relative weight loss. Participants using tirzepatide lost an average of 22.8 kg and participants on semaglutide lost an average of 15.0 kg.2.' In key secondary endpoints, tirzepatide was superior across all weight reduction targets with 64.6 per cent of participants treated with tirzepatide achieving at least 15.0 per cent weight loss compared to 40.1 per cent on semaglutide. Additionally, participants treated with tirzepatide achieved a superior average waist circumference reduction of 7.2 in (18.4 cm), while those treated with semaglutide saw an average reduction of 5.1 in (13.0 cm). 'Thanks to the latest advancements in obesity management medications, more physicians and patients are witnessing significant weight reduction beyond what they have seen before,' said Louis J. Aronne, MD, FACP, DABOM, director of the Comprehensive Weight Control Center and the Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medicine, obesity expert at New York-Presbyterian/Weill Cornell Medical Center, and investigator of SURMOUNT-5,' as per the statement. 'The SURMOUNT-5 head-to-head results demonstrated that tirzepatide led to greater weight reduction compared to semaglutide, providing further evidence to support tirzepatide as an effective option for obesity management.' 'Obesity is a chronic disease that requires comprehensive management, and Lilly is committed to supporting people with obesity and enhancing the standard of care in obesity management in India', said Winselow Tucker, President and General Manager, Eli Lilly and Company (India). 'The results from the SURMOUNT 5 trial provide robust evidence supporting Mounjaro (tirzepatide) as an effective option for obesity management in India.' The safety profile of tirzepatide in SURMOUNT-5 was consistent with previous SURMOUNT trials. Adverse events reported during the trial were primarily gastrointestinal-related and were generally mild to moderate in severity. During the trial, 6.1 per cent of participants taking tirzepatide discontinued treatment due to adverse events, compared to eight per cent of participants taking semaglutide. However, the study was not powered to compare the safety and tolerability of tirzepatide and the safety and tolerability of semaglutide. Tirzepatide is a weight loss drug for adults with obesity or with overweight who also have weight-related medical problems, as Zepbound in the US and Mounjaro in some countries outside of the US Tirzepatide is also commercialised as Mounjaro for adults with type 2 diabetes in the US and in some countries outside of the US. Semaglutide is a drug used as Wegovy for people living with obesity or for overweight adults who also have weight-related medical problems and Ozempic for people with type 2 diabetes. (ANI)
Forbes
27-03-2025
- Business
- Forbes
The Weill Family Foundation Donates $50 Million For New Cancer Hub
A $50 million gift by the Weill Family Foundation is bringing together four leading research institutions to form the Weill Cancer Hub East. The new partnership, aimed at advancing immunotherapy as a treatment strategy for cancer, involves Princeton University, The Rockefeller University, Weill Cornell Medicine and the Ludwig Institute for Cancer Research. Directed by benefactors Joan and Sanford I. Weill, the former CEO of Citigroup, the gift will be matched by funding from each of the partner institutions that will total more than $125 million when combined. 'The Weill Cancer Hub East will offer doctors and scientists a tremendous opportunity to revolutionize the treatment of cancer, a disease that complicates so many lives,' said Sandy Weill, founder of the Weill Family Foundation, in a press release. 'With the best minds in the field armed with the most advanced research techniques, the Weill Cancer Hub East will seek to elevate immunotherapy and improve patient care for people battling cancer. Joan and I could not be more excited about the endless possibilities of this special partnership—investment in science and medicine is our labor of love," Weill added. Immunotherapy is a relatively new cancer treatment approach that uses a patient's own immune cells to recognize and treat cancer.'How we can increase the effectiveness of immunotherapy across all cancer types and patients is one of the scientific questions that most needs answering,' said Dr. Robert A. Harrington, the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, in the release. The Weill Cancer Hub East will form multidisciplinary teams of experts in cancer biology, computational analysis and artificial intellience, cancer clinical trials, immunology, nutrition and metabolism to explore the relationship between solid tumors and the environment where they form and grow. A three-person scientific steering committee will oversee the hub's scientific activities. The committee members are: In addition, a leadership committee, made up of leaders from Princeton, Rockefeller, Weill Cornell Medicine and Ludwig, along with representatives from the Weill Family Foundation, will direct the hub's scientific strategy, according to the release. This is not the first example of the Weill Family Foundation's investment in multidisciplinary, biomedical science. Their $106 million gift led to the founding of the Weill Neurohub in 2019. That center brings together scientists and clinicians from the University of California at San Francisco, the University of California at Berkeley, the University of Washington and the Allen Institute to develop new treatments for neurological and psychiatric disease. A graduate of Cornell University, Sanford "Sandy" Weill made his fortune in the financial services industry. His first job was as a runner for Bear Stearns in 1955, earning $150 a week. Later he formed a brokerage firm with partners and built it into Shearson Loeb Rhoads, which he sold to American Express for nearly $1 billion in 1981. Weill served as CEO of Citigroup until 2003 and chairman until 2006. According to the news release, the Weill family and the Weill Family Foundation have given more than $1 billion in total for various causes in the United States and around the globe, ranging from education, social causes, music and the arts to medical research and patient care.
